Dexcom (DXCM) Falls 6% After Abbott Cuts Diabetes Outlook

Dexcom (DXCM) fell about 6% on Oct. 21 after rival Abbott cut its diabetes care growth outlook, making it a top S&P 500 decliner as the index gained.

Lead

What Happened to Dexcom Stock?

Dexcom stock fell about 6% because Abbott's guidance cut raised questions about demand and pricing across the glucose monitoring market. Abbott said it expects diabetes care growth in the low-to-mid single digits over the next several quarters. Its prior outlook was high single digits. Management cited pricing pressure outside the United States and slower-than-expected reimbursement progress for some patient groups.

Abbott shares also fell, by roughly 3% to 4%, as the company trimmed its full-year comparable sales growth forecast to about 6%. The earlier range was 6.5% to 7.5%. The revision reflected softer expectations in electrophysiology as well as diabetes care. Abbott also announced plans to spin off its nutrition business, which includes Similac, Pedialyte and Ensure, into a separate public company by the end of 2027.

How Did Abbott's Third-Quarter Results Look?

Abbott's quarter was solid on the surface. Adjusted earnings were $1.42 a share on revenue of about $13.01 billion. Comparable sales growth was 7.0%.

Diabetes care revenue reached about $2.19 billion, up 6.7% on a comparable basis. Continuous glucose monitor sales grew 7.7% on a comparable basis. The company reaffirmed its full-year adjusted earnings guidance of $5.50 to $5.55 a share. The market's focus was on the forward growth rate rather than the quarter itself.

Abbott also received US Food and Drug Administration approval for Libre Duo, a dual glucose-ketone sensor. It plans to launch the product in the United States in December 2026. The device would add a feature that competing sensors do not yet offer.

Why Is Abbott's Outlook a Read-Through for Dexcom?

Abbott's outlook matters for Dexcom because the two companies dominate a market that is expanding but increasingly competitive. Both sell sensors to people with type 1 and type 2 diabetes and depend on payer coverage and pricing. A slowdown in reimbursement expansion or international price erosion at one company points to similar headwinds at the other.

Investors had already marked Dexcom lower in the run-up to earnings. The shares traded near $83 in mid-October, so the Oct. 21 drop extended a decline into the company's report. The stock sits well below the levels reached earlier in the cycle, which left little cushion for a weaker industry signal.

What Comes Next for Dexcom?

Dexcom reports third-quarter 2026 results on Oct. 29 at 4:30 p.m. Eastern Time. That release will show whether the pricing and reimbursement pressures Abbott described appear in Dexcom's own figures. Revenue growth, gross margin and 2026 guidance will draw the most attention.

Two scenarios frame the report. If Dexcom holds its growth guidance, the Oct. 21 move will look like a sympathy reaction to a competitor's outlook. If it signals similar moderation in coverage expansion or international pricing, the market will treat Abbott's comments as an industry-wide shift. Abbott's Libre Duo launch in December adds a product-cycle question to the competitive picture.

Market Context

The S&P 500 gained on the day while large-cap medical technology names lagged. Dexcom's decline was among the sharpest in the index, a notable divergence given the broader advance. For investors tracking a healthcare etf, the move shows how a single competitor's guidance can pull a mid-cap medical device name against the tape.

Outlook

Dexcom's 6% drop on Oct. 21 reflected Abbott's cut to diabetes care growth, from high single digits to low-to-mid single digits, rather than any company-specific news. The Oct. 29 earnings report is the next test of whether the slowdown is confined to Abbott or extends across continuous glucose monitoring.